Trial Profile
A phase III, randomised, double blind, placebo controlled and open label phase, multicentre study to investigate the efficacy and safety of BTX-A-HAC NG in the treatment of moderate to severe glabellar lines, and assess the long term efficacy and safety of BTX-A-HAC NG following repeated treatments in this indication
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2022
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Registrational; Therapeutic Use
- Sponsors Ipsen
- 31 May 2022 According to a Galderma media release, Pooled data from two phase III studies (NCT02353871 and NCT02493946) will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022.
- 30 Jan 2017 Status changed from active, no longer recruiting to completed.
- 27 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Dec 2016.